Ratings StemRIM

Equities

4599

JP3399690001

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 EDT			5-day change	1st Jan Change
475 ^JPY	+0.42%		+7.22%	-17.82%

03-13	StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	CI
01-31	StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
STEMRIM	-17.82%	185M	-
CSL LIMITED	-3.93%	86.16B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.17B	A-
BIOGEN INC.	-16.48%	31.47B	B-
UCB	+54.63%	25.24B	A
BIOMARIN PHARMACEUTICAL INC.	-13.58%	15.82B	C
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B	B
SWEDISH ORPHAN BIOVITRUM AB	+4.57%	8.84B	B+
INNOVENT BIOLOGICS, INC.	-2.11%	7.93B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes